Joel M. Kremer

39.1k total citations · 10 hit papers
322 papers, 23.2k citations indexed

About

Joel M. Kremer is a scholar working on Rheumatology, Genetics and Hematology. According to data from OpenAlex, Joel M. Kremer has authored 322 papers receiving a total of 23.2k indexed citations (citations by other indexed papers that have themselves been cited), including 269 papers in Rheumatology, 103 papers in Genetics and 85 papers in Hematology. Recurrent topics in Joel M. Kremer's work include Rheumatoid Arthritis Research and Therapies (259 papers), Chronic Lymphocytic Leukemia Research (101 papers) and Systemic Lupus Erythematosus Research (93 papers). Joel M. Kremer is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (259 papers), Chronic Lymphocytic Leukemia Research (101 papers) and Systemic Lupus Erythematosus Research (93 papers). Joel M. Kremer collaborates with scholars based in United States, United Kingdom and Canada. Joel M. Kremer's co-authors include Michael E. Weinblatt, Roy Fleischmann, Jeffrey D. Greenberg, George Reed, Paul Emery, David Gruben, Samuel H. Zwillich, Larry W. Moreland, Daniel Burge and Edward Keystone and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Joel M. Kremer

314 papers receiving 22.2k citations

Hit Papers

A Trial of Etanercept, a Recombinant Tumor Necrosis Facto... 1988 2026 2000 2013 1999 2008 2003 2012 2006 500 1000 1.5k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. A Trial of Etanercept, a Recombinant Tumor Necrosis Factor Receptor:Fc Fusion Protein, in Patients with Rheumatoid Arthritis Receiving Methotrexate
    1999 1.6k citations Michael E. Weinblatt, Joel M. Kremer et al. New England Journal of Medicine profile →
  2. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial
    2008 866 citations Paul Emery, Joel M. Kremer et al. Annals of the Rheumatic Diseases profile →
  3. Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig
    2003 807 citations Joel M. Kremer, René Westhovens et al. New England Journal of Medicine profile →
  4. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis
    2012 790 citations Joel M. Kremer, Carol A. Connell et al. New England Journal of Medicine profile →
  5. Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis
    2006 558 citations Joel M. Kremer, Larry W. Moreland et al. profile →
  6. Drug binding to human alpha-1-acid glycoprotein in health and disease.
    1988 501 citations Joel M. Kremer et al. profile →
  7. Tofacitinib (CP‐690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve‐month data from a twenty‐four–month phase III randomized radiographic study
    2013 456 citations Joel M. Kremer, Stanley Cohen et al. profile →
  8. Dietary fish oil and olive oil supplementation in patients with Rheumatoid Arthritis clinical and immunologic effects
    1990 435 citations Joel M. Kremer et al. profile →
  9. Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis
    2013 366 citations Joel M. Kremer et al. profile →
  10. Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial
    2018 294 citations Gerd R Burmester, Joel M. Kremer et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel M. Kremer United States 77 15.2k 6.9k 5.0k 4.1k 2.5k 322 23.2k
Roy Fleischmann United States 69 16.7k 1.1× 8.1k 1.2× 6.4k 1.3× 3.9k 1.0× 2.8k 1.1× 347 22.9k
Edward Keystone Canada 69 17.0k 1.1× 7.8k 1.1× 6.8k 1.3× 4.2k 1.0× 2.0k 0.8× 404 24.5k
Vibeke Strand United States 73 15.4k 1.0× 5.6k 0.8× 6.3k 1.2× 2.0k 0.5× 1.5k 0.6× 522 22.9k
Ben A. C. Dijkmans Netherlands 83 18.3k 1.2× 6.1k 0.9× 6.3k 1.2× 2.1k 0.5× 1.9k 0.8× 332 25.0k
Deborah Symmons United Kingdom 87 16.0k 1.1× 5.1k 0.7× 6.9k 1.4× 2.3k 0.6× 1.3k 0.5× 396 27.2k
Daniel E. Fürst United States 64 12.3k 0.8× 5.3k 0.8× 4.6k 0.9× 2.6k 0.6× 1.4k 0.6× 258 22.1k
Ferdinand C. Breedveld Netherlands 67 15.2k 1.0× 5.4k 0.8× 5.4k 1.1× 2.6k 0.6× 2.3k 0.9× 182 21.9k
Daniel Aletaha Austria 64 15.0k 1.0× 5.4k 0.8× 4.7k 0.9× 2.4k 0.6× 1.9k 0.8× 327 21.2k
Tore K Kvien Norway 84 18.4k 1.2× 5.4k 0.8× 5.5k 1.1× 1.5k 0.4× 1.1k 0.4× 537 28.6k
Ronald van Vollenhoven Sweden 80 20.6k 1.4× 6.8k 1.0× 10.0k 2.0× 4.4k 1.1× 2.8k 1.1× 512 27.7k

Countries citing papers authored by Joel M. Kremer

Since Specialization
Citations

This map shows the geographic impact of Joel M. Kremer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel M. Kremer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel M. Kremer more than expected).

Fields of papers citing papers by Joel M. Kremer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel M. Kremer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel M. Kremer. The network helps show where Joel M. Kremer may publish in the future.

Co-authorship network of co-authors of Joel M. Kremer

This figure shows the co-authorship network connecting the top 25 collaborators of Joel M. Kremer. A scholar is included among the top collaborators of Joel M. Kremer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel M. Kremer. Joel M. Kremer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Paudel, Misti L., Nancy A. Shadick, Michael E. Weinblatt, et al.. (2025). Development and External Validation of a Multivariable Predictive Model for Progression to Difficult‐to‐Treat Rheumatoid Arthritis in Biologic‐Experienced Patients. Arthritis Care & Research. 78(1). 54–65.
2.
Baker, Joshua F., Ted R. Mikuls, Geoffrey M. Thiele, et al.. (2024). Metabolic Syndrome, Adipokines, and Response to Advanced Therapies in Rheumatoid Arthritis. Arthritis & Rheumatology. 77(3). 263–271. 2 indexed citations
3.
4.
Dua, Anisha B., Stefano Fiore, Dimitrios A. Pappas, et al.. (2023). Clinical Outcomes in Patients with Rheumatoid Arthritis After Switching Between Interleukin-6-Receptor Inhibitors and Janus Kinase Inhibitors: Findings from an Observational Study. Rheumatology and Therapy. 10(6). 1753–1768. 1 indexed citations
5.
Kremer, Joel M., Clifton O. Bingham, Laura C. Cappelli, et al.. (2021). Postapproval Comparative Safety Study of Tofacitinib and Biological Disease‐Modifying Antirheumatic Drugs: 5‐Year Results from a United States–Based Rheumatoid Arthritis Registry. ACR Open Rheumatology. 3(3). 173–184. 105 indexed citations
6.
7.
Mellors, Theodore, Johanna B. Withers, Asher Ameli, et al.. (2020). Clinical Validation of a Blood-Based Predictive Test for Stratification of Response to Tumor Necrosis Factor Inhibitor Therapies in Rheumatoid Arthritis Patients. SHILAP Revista de lepidopterología. 3(1). 91–104. 30 indexed citations
8.
9.
Lillegraven, Siri, Jeffrey D. Greenberg, George Reed, et al.. (2019). Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS ONE. 14(1). e0210459–e0210459. 39 indexed citations
10.
Guan, Yuanfang, Hongjiu Zhang, Daniel Quang, et al.. (2019). Machine Learning to Predict Anti–Tumor Necrosis Factor Drug Responses of Rheumatoid Arthritis Patients by Integrating Clinical and Genetic Markers. Arthritis & Rheumatology. 71(12). 1987–1996. 94 indexed citations
11.
Cohen, Stanley, Joel M. Kremer, Kimberly J. Dandreo, et al.. (2019). Outcomes of infliximab dose escalation in patients with rheumatoid arthritis. Clinical Rheumatology. 38(9). 2501–2508. 1 indexed citations
12.
Burmester, Gerd R, Iain B. McInnes, Joel M. Kremer, et al.. (2018). Mavrilimumab, a Fully Human Granulocyte–Macrophage Colony‐Stimulating Factor Receptor α Monoclonal Antibody. Arthritis & Rheumatology. 70(5). 679–689. 62 indexed citations
13.
O’Dell, James R., Stanley Cohen, Carter Thorne, & Joel M. Kremer. (2018). Treatment of rheumatoid arthritis in the USA: premature use of tumor necrosis factor inhibition and underutilization of concomitant methotrexate. Open Access Rheumatology Research and Reviews. Volume 10. 97–101. 2 indexed citations
14.
Alemao, E., Heather J. Litman, Seán Connolly, et al.. (2018). Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry. The Journal of Rheumatology. 45(10). 1353–1360. 2 indexed citations
15.
Weinblatt, Michael E., Iain B. McInnes, Joel M. Kremer, et al.. (2017). A Randomized Phase II b Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis. Arthritis & Rheumatology. 70(1). 49–59. 72 indexed citations
16.
Zhang, Jie, Ying Shan, George Reed, et al.. (2011). Thresholds in disease activity for switching biologics in rheumatoid arthritis patients: Experience from a large US cohort. Arthritis Care & Research. 63(12). 1672–1679. 42 indexed citations
17.
Kremer, Joel M.. (2006). Methotrexate pharmacogenomics. Annals of the Rheumatic Diseases. 65(9). 1121–1123. 24 indexed citations
18.
Greenberg, Jeffrey D., Clifton O. Bingham, Steven B. Abramson, et al.. (2006). Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. Arthritis Care & Research. 55(4). 543–550. 7 indexed citations
19.
Bingham, Clifton O., Anthony Sebba, Gary Ruoff, et al.. (2006). Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies. Lara D. Veeken. 46(3). 496–507. 94 indexed citations
20.
Kremer, Joel M., René Westhovens, Marc Léon, et al.. (2003). Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig. New England Journal of Medicine. 349(20). 1907–1915. 807 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Roy Fleischmann Breakdown of academic impact, for papers by Edward Keystone Breakdown of academic impact, for papers by Vibeke Strand Breakdown of academic impact, for papers by Ben A. C. Dijkmans Breakdown of academic impact, for papers by Deborah Symmons Breakdown of academic impact, for papers by Daniel E. Fürst Breakdown of academic impact, for papers by Ferdinand C. Breedveld Breakdown of academic impact, for papers by Daniel Aletaha Breakdown of academic impact, for papers by Tore K Kvien Breakdown of academic impact, for papers by Ronald van Vollenhoven
Rankless by CCL
2026